Article Data

  • Views 526
  • Dowloads 129

Original Research

Open Access

Cervical atypical glandular cells and false negative HPV testing: a dramatic reality of the wrong test at the right place

  • W.A.A. Tjalma1,*,
  • C.E. Depuydt2

1Department of Gynecology and Gynecologic Oncology, Antwerp University Hospital, University of Antwerp, Antwerp

2Department of Molecular Pathology (RIATOL), Sonic Healthcare Benelux, Antwerp (Belgium)

DOI: 10.12892/ejgo24042014 Vol.35,Issue 2,March 2014 pp.117-120

Published: 10 March 2014

*Corresponding Author(s): W.A.A. Tjalma E-mail: Wiebren.Tjalma@uza.be

Abstract

Background: Due to cervical cancer screening the number of squamous cancer have declined. The number of adenocarcinomas (ADCs) does appear to be rising. ADCs are often missed and human papillomavirus (HPV) testing could be helpful in detecting these abnormalities earlier. Case: A 36-year-old woman, who had a normal smear three years earlier, had a pap smear with atypical glandular cells. The L1 HPV test showed that there was no HPV infection. Other HPV tests which looked at E6 and E7 showed an infection with HPV 16. Due to unknown reasons, no action was taken regarding the atypical glandular cells. Two years later the patient was diagnosed with a FIGO Stage IVb ADC of the cervix. The L1 HPV test was still negative and the E6/E7 HPV test was still positive. Despite several multiple treatment modalities she succumbed of her disease two years later leaving behind a young family. Conclusion: HPV test looking only at L1 can give false negative results if the virus is integrated in the human genome.

Keywords

Human papillomavirus; HPV; Adenocarcinoma; L1; E6; E7; Integration; False negative; Cervical cancer; Prophylactic vaccination; Screening; Cross-protection; HPV testing.

Cite and Share

W.A.A. Tjalma,C.E. Depuydt. Cervical atypical glandular cells and false negative HPV testing: a dramatic reality of the wrong test at the right place. European Journal of Gynaecological Oncology. 2014. 35(2);117-120.

References

[1] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[2] Depuydt C.E., Criel A.M., Benoy I.H., Arbyn M., Vereecken A.J., Bogers J.J.: “Changes in Type-specific Human Papillomavirus Load Predict Progression to Cervical Cancer”. J. Cell. Mol. Med., 2012, 16, 3096.

[3] Seoud M., Tjalma W.A., Ronsse V.: “Cervical adenocarcinoma: moving towards better prevention”. Vaccine, 2011, 29, 9148.

[4] Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B. et al.: “HERACLES/SCALE Study Group. Dif fe rences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe”. Int. J. Cancer, 2013, 132, 854.

[5] de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaus ter meier J.E., Lloveras B. et al.: “Retrospective International Survey and HPV Time Trends Study Group. Humanpapillo ma virus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study”. Lancet Oncol., 2010, 11, 1048.

[6] Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S. et al.: “Overview of the European and North American studies on HPV testing in primary cervical cancer screening”. Int. J. Cancer, 2006, 119, 1095.

[7] Tjalma W.A., Depuydt C.E.: “Don’t forget HPV-45 in cervical cancer screening”. Am. J. Clin. Pathol., 2012, 137, 161.

[8] Tjalma W.A.: “Cervical cancer and prevention by vaccination: results from recent trials”. Ann. Oncol., 2006, 17, 217.

[9] Trinh X.B., Bogers J.J., Van Marck E.A., Tjalma W.A.: “Treatment policy of neuroendocrine small cell cancer of the cervix”. Eur. J. Gynaecol. Oncol., 2004, 25, 40.

[10] Bertrand M., Lickrish G.M., Colgan T.J.: “The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment”. Am. J. Obstet. Gynecol., 1987, 157, 21.

[11] Kusanagi Y., Kojima A., Mikami Y., Kiyokawa T., Sudo T., Yamaguchi S. et al.: “Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype”. Am. J. Pathol., 2010, 177, 2169.

[12] Bruni L., Diaz M., Castellsagué X., Ferrer E., Bosch F.X., de Sanjosé S.: “Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings”. J. Infect. Dis., 2010, 15, 202, 1789.

[13] Clifford G., Franceschi S.: “Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix”. Int. J. Cancer, 2008, 122, 1684.

[14] Tjalma W.A.A.: “Chapter 3: Prophylactic HPV vaccines and their efficacy”. Recent Advances in Cervical Cancer; Editor: Iztok Takac 2011; Published by Transworld Research Network, India. 2011, 23.

[15] Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S. M., Castellsagué X. et al.: “HPV PATRICIA Study Group. Over-all efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial”. Lancet Oncol., 2012, 13, 89.

[16] Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P. et al.: “HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, doubleblind PATRICIA trial”. Lancet Oncol., 2012, 13, 100.

[17] Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.: “2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests”. Am. J. Obstet. Gynecol., 2007, 197, 346.

[18] Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.: “2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ”. J. Low Genit. Tract. Dis., 2007, 11, 223.

[19] Zhao C., Florea A., Onisko A., Austin R.M.: “Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods”. Gynecol. Oncol., 2009, 114, 383.

[20] Wright T.C. Jr, Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: “American Society for Colposcopy and Cervical Pathology. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia”. Am. J. Obstet. Gynecol., 2003, 189, 295.

[21] Wright T.C. Jr, Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: “2001 ASCCP-sponsored Consensus Workshop. 2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia”. J. Low Genit. Tract. Dis., 2003, 7, 154.

[22] Badaracco G., Venuti A., Sedati A., Marcante M.L.: “HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness”. J. Med. Virol., 2002, 67, 574.

[23] Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P. et al.: “Type-dependent integration frequency of human papillomavirus genomes in cervical lesions”. Cancer Res., 2008, 68, 307.

[24] Qu W., Jiang G., Cruz Y., Chang C.J., Ho G.Y., Klein R.S. et al.: “PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems”. J. Clin. Microbiol., 1997, 35, 1304.

[25] Morris B.J.: “Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region”. Clin. Chem. Lab. Med., 2005, 43, 1171.

[26] Depuydt C.E., Boulet G.A., Horvath C.A., Benoy I.H., Vereecken A. J., Bogers J.J.: “Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types”. J. Cell. Mol. Med., 2007, 11, 881.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top